In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure (HF) and peripheral artery disease (PAD) frequently coexist.
• Patients with both HF and PAD have a worse prognosis and limited treatment options.
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown benefits in HF.

Purpose of the Study:

• To evaluate the efficacy of dapagliflozin in patients with heart failure and concomitant peripheral artery disease.
• To assess the impact of dapagliflozin on cardiovascular outcomes in this specific patient subgroup.

Main Methods:

• Patient-level data meta-analysis from the DAPA-HF and DELIVER randomized controlled trials.
• Inclusion of patients with and without peripheral artery disease.
• Assessment of primary composite endpoint (heart failure events and cardiovascular death).

Main Results:

• Dapagliflozin significantly reduced the risk of heart failure events in patients with peripheral artery disease.
• The treatment effect of dapagliflozin was consistent across patients with and without peripheral artery disease.
• No significant increase in adverse events was observed in patients with peripheral artery disease.

Conclusions:

• Dapagliflozin is effective in reducing heart failure events in patients with heart failure and peripheral artery disease.
• The benefits of dapagliflozin extend to patients with comorbid peripheral artery disease.
• Dapagliflozin represents a valuable therapeutic option for patients with heart failure and peripheral artery disease.